621 related articles for article (PubMed ID: 21617198)
1. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
4. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
5. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.
Panichi V; Rosati A; Bigazzi R; Paoletti S; Mantuano E; Beati S; Marchetti V; Bernabini G; Grazi G; Rizza GM; Migliori M; Giusti R; Lippi A; Casani A; Barsotti G; Tetta C;
Nephrol Dial Transplant; 2011 Aug; 26(8):2641-8. PubMed ID: 21325348
[TBL] [Abstract][Full Text] [Related]
6. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
Minutolo R; Conte G; Cianciaruso B; Bellizzi V; Camocardi A; De Paola L; De Nicola L
Nephrol Dial Transplant; 2012 Jul; 27(7):2880-6. PubMed ID: 22319218
[TBL] [Abstract][Full Text] [Related]
7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
Rossert J; Gassmann-Mayer C; Frei D; McClellan W
Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
[TBL] [Abstract][Full Text] [Related]
9. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
[TBL] [Abstract][Full Text] [Related]
11. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
Regidor D; McClellan WM; Kewalramani R; Sharma A; Bradbury BD
Nephrol Dial Transplant; 2011 May; 26(5):1583-91. PubMed ID: 20861195
[TBL] [Abstract][Full Text] [Related]
12. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
[TBL] [Abstract][Full Text] [Related]
13. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
[TBL] [Abstract][Full Text] [Related]
14. Low testosterone and anaemia in men with type 2 diabetes.
Grossmann M; Panagiotopolous S; Sharpe K; MacIsaac RJ; Clarke S; Zajac JD; Jerums G; Thomas MC
Clin Endocrinol (Oxf); 2009 Apr; 70(4):547-53. PubMed ID: 18702678
[TBL] [Abstract][Full Text] [Related]
15. A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: better results for less work.
Lines SW; Lindley EJ; Tattersall JE; Wright MJ
Nephrol Dial Transplant; 2012 Jun; 27(6):2425-9. PubMed ID: 22207330
[TBL] [Abstract][Full Text] [Related]
16. Hypogonadism in males with chronic kidney disease: another cause of resistance to erythropoiesis-stimulating agents?
Stenvinkel P; Bárány P
Contrib Nephrol; 2012; 178():35-39. PubMed ID: 22652713
[TBL] [Abstract][Full Text] [Related]
17. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study.
Cases-Amenós A; Martínez-Castelao A; Fort-Ros J; Bonal-Bastons J; Ruiz MP; Vallés-Prats M; Coll-Piera E; Galcerán-Gui JM;
Nefrologia; 2014; 34(2):189-98. PubMed ID: 24658193
[TBL] [Abstract][Full Text] [Related]
19. Shortened red blood cell lifespan is related to the dose of erythropoiesis-stimulating agents requirement in patients on hemodialysis.
Sato Y; Mizuguchi T; Shigenaga S; Yoshikawa E; Chujo K; Minakuchi J; Kawashima S
Ther Apher Dial; 2012 Dec; 16(6):522-8. PubMed ID: 23190511
[TBL] [Abstract][Full Text] [Related]
20. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]